Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation

Cancer Research

Volumn 72, Issue 21, 2012, Pages 5454-5462

  Popova, Tatiana ^a,b   Manié, Elodie ^a,b   Rieunier, Guillaume ^a,b   Caux Moncoutier, Virginie ^c   Tirapo, Carole ^c   Dubois, Thierry ^a,d   Delattre, Olivier ^a,b   Sigal Zafrani, Brigitte ^c   Bollet, Marc ^b   Longy, Michel ^f   Houdayer, Claude ^c,e   Sastre Garau, Xavier ^c   Vincent Salomon, Anne ^a,b,c   Stoppa Lyonnet, Dominique ^a,b,c,e   Stern, Marc Henri ^a,b,c  

^a Centre de Recherche   (France)

^b INSTITUT CURIE   (France)

^c Department of Tumor Biology ^*  (France)

^d Translational Department   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BASAL LIKE BREAST CARCINOMA; BREAST CARCINOMA; CONTROLLED STUDY; COPY NUMBER VARIATION; EPIGENETICS; FEMALE; FRAGMENTATION REACTION; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC SCREENING; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; MAJOR CLINICAL STUDY; PLOIDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS;

ADENOCARCINOMA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; GENOMIC INSTABILITY; HUMANS; PLOIDIES; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SENSITIVITY AND SPECIFICITY;

EID: 84868240146     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1470     Document Type: Article

References (53)

1. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26:2568-81.
2. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutationsand a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-5.
3. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patternsof DNAcopynumberalteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006;45:1033-40.
4. Melchor L, Honrado E, Garcia MJ, Alvarez S, Palacios J, Osorio A, et al. Distinctgenomicaberration patternsarefound infamilial breastcancer associated with different immunohistochemical subtypes. Oncogene 2008;27:3165-75.
5. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberra-tionsin basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010;121:575-89.
6. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012;12: 68-78.
7. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
8. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17:1082-9.
9. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, et al. High-resolution a CGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 2007;8:R215.
10. Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Stei-narsdottir M, Valgeirsdottir S, et al. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009;11:R47.
11. Joosse SA, Brandwijk KI, Mulder L, Wesseling J, Hannemann J, Nederlof PM. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer 2011;50: 71-81.
12. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-53.
13. Vollebergh MA, Jonkers J, Linn SC. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cel Mol Life Sci 2012;69:223-45.
14. Focken T, Steinemann D, Skawran B, Hofmann W, Ahrens P, Arnold N, et al. Human BRCA1-associated breast cancer: no increase in numer-ical chromosomal instability compared tosporadictumors. Cytogenet Genome Res 2011;135:84-92.
15. Johannsdottir HK, Jonsson G, Johannesdottir G, Agnarsson BA, Eerola H, Arason A, et al. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. Int J Cancer 2006;119:1052-60.
16. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997;57:1222-7.
17. Wessels LF, van Welsem T, Hart AA, van't Veer LJ, Reinders MJ, Nederlof PM. Molecular classification of breast carcinomas by com-parative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 2002;62:7110-7.
18. Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, et al. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat 2010;123: 661-77.
19. Jonsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C, et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010;12:R42.
20. Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hooger-brugge N, et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breastcarcinomaswitharray-CGH. Breast Cancer Res Treat 2009;116:479-89.
21. Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MT, van de Vijver MJ, et al. Indicators of homologous recombination deficiency in breast cancer and association with response to neoad-juvant chemotherapy. Ann Oncol 2011;22:870-6.
22. Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Schmidt MK, van Beers EH, et al. An a CGH classifier derived from BRCA1-mutated breast cancerand benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011;22: 1561-70.
23. Popova T, Manie E, Stoppa-Lyonnet D, Rigaill G, Barillot E, Stern MH. Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol 2009;10:R128. Available from: http://bioinfo-out.curie.fr/projects/ snp-gap/
24. Manie E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009;69:663-71.
25. Vincent-Salomon A, Gruel N, Lucchesi C, Mac Grogan G, Dendale R, Sigal-Zafrani B, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007; 9:R24.
26. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, et al. Frequent PTEN genomic alterations and activated phosphatidy-linositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008;10:R101.
27. Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, et al. Search for a gene-expression signature of breast cancer local recur-rence in young women. Clin Cancer Res 2012;18:1704-15.
28. De Rose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011;17:1514-20.
29. De Plater L, Lauge A, Guyader C, Poupon MF, Assayag F, de Cremoux P, et al. Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 muta-tion. Br J Cancer2010;103:1192-200.
30. Wellcome Trust Sanger Institute Cancer Genome Project. Available from: http://www.sanger.ac.uk/genetics/CGP
31. Stephens PJ, Mc Bride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009;462:1005-10.
32. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006;66:41-5.
33. Xu J, Huo D, Chen Y, Nwachukwu C, Collins C, Rowell J, et al. Cp G island methylation affects accessibility of the proximal BRCA1 pro-moter to transcription factors. Breast Cancer Res Treat 2010;120: 593-601.
34. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-50. Available from: http://www.sanger.ac.uk/ genetics/CGP/cosmic/
35. Houdayer C, Moncoutier V, Champ J, Weber J, Viovy JL, Stoppa-Lyonnet D. Enhanced mismatch mutation analysis: simultaneous detection of point mutations and large scale rearrangements by capillary electrophoresis, application to BRCA1 and BRCA2. Methods Mol Biol 2010;653:147-80.
36. Natrajan R, Mackay A, Lambros MB, Weigelt B, Wilkerson PM, Manie E, et al. A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. J Pathol 2012;227:29-41.
37. Rasband WS. Image J, U.S. National Institutes of Health, Bethesda, MD, USA, 1997-2012.Availablefrom: http://imagej.nih.gov/ij/
38. Staaf J, Vallon-Christersson J, Lindgren D, Juliusson G, Rosenquist R, Hoglund M, et al. Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios. BMC Bioinformatics 2008;9:409.
39. Storchova Z, Kuffer C. The consequences of tetraploidy and aneu-ploidy. J Cell Sci 2008;121:3859-66.
40. Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin P, Naume B, et al. Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2010;2:38-47.
41. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006;16:1465-79.
42. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27-40.
43. Mrasek K, Schoder C, Teichmann AC, Behr K, Franze B, Wilhelm K, et al.Global screen in gandext ended nomenclature for 230 aphidicol in-inducible fragile sites, including 61 yet unreported ones. Int J Oncol 2010;36:929-40.
44. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis oftumors. Proc Natl Acad Sci U S A2010;107:16910-5.
45. Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS, et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007;39:1338-49.
46. Fukasawa K. Centrosome amplification, chromosome instability and cancer development. Cancer Lett 2005;230:6-19.
47. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is asso-ciated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010;17:688-95.
48. Feng Z, Scott SP, Bussen W, Sharma GG, Guo G, Pandita TK, et al. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci U S A 2011;108:686-91.
49. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451:1111-5.
50. Moller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, et al. Genetic epidemiologyof BRCAmutations-familyhistorydetectslessthan50% of the mutation carriers. Eur J Cancer2007;43:1713-7.
51. Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancertherapy. Nat Rev Clin Oncol 2010;7:718-24.
52. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.
53. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhib-itor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30:372-9.